Top Page
Genedrive
(LSE:GDR)
Genedrive (GDR) vs. iShares MSCI United Kingdom ETF (EWC)
Genedrive Business Overview & Revenue Model
Genedrive Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 954.00K | 764.00K | 501.00K | 55.00K | 49.00K | 687.00K |
| Gross Profit | 764.00K | 764.00K | 254.00K | -199.00K | -3.82M | -3.82M |
| EBITDA | -5.36M | -5.36M | -7.49M | -5.70M | -5.37M | -1.37M |
| Net Income | -5.23M | -5.23M | -7.08M | -5.15M | -4.67M | -691.00K |
Balance Sheet | ||||||
| Total Assets | 2.81M | 2.81M | 6.80M | 4.51M | 6.62M | 4.88M |
| Cash, Cash Equivalents and Short-Term Investments | 1.18M | 1.18M | 5.19M | 2.60M | 4.59M | 2.57M |
| Total Debt | 0.00 | 0.00 | 19.00K | 241.00K | 16.00K | 119.00K |
| Total Liabilities | 1.38M | 1.38M | 1.44M | 2.47M | 1.01M | 1.28M |
| Stockholders Equity | 1.44M | 1.44M | 5.36M | 2.04M | 5.61M | 3.59M |
Cash Flow | ||||||
| Free Cash Flow | -5.12M | -5.12M | -3.80M | -3.83M | -4.67M | -5.29M |
| Operating Cash Flow | -5.10M | -5.10M | -3.77M | -3.78M | -4.61M | -5.18M |
| Investing Cash Flow | -23.00K | -23.00K | 1.00K | -37.00K | 45.00K | 33.00K |
| Financing Cash Flow | 1.12M | 1.12M | 6.36M | 1.82M | 6.58M | -456.00K |
Genedrive Technical Analysis
Genedrive Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | £114.80M | 19.63 | 8.71% | ― | -1.43% | 28.57% | |
52 Neutral | £26.30M | -6.96 | -213.66% | ― | 39.88% | 81.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £1.36B | -9.32 | -26.01% | ― | 22.03% | 20.01% | |
45 Neutral | £15.69M | -6.58 | -90.48% | ― | 37.39% | -126.19% | |
44 Neutral | £9.01M | -0.94 | -153.92% | ― | 90.42% | 79.21% | |
43 Neutral | £27.31M | -0.44 | 425.97% | ― | -4.48% | 61.09% |
Genedrive Corporate Events
Genedrive plc, a UK-based specialist in point-of-care pharmacogenetic testing for emergency and personalised medicine, has built a product suite around its Genedrive MT-RNR1 ID Kit for rapid antibiotic decision-making in neonatal intensive care and its CYP2C19 ID Kit for guiding antiplatelet choice in stroke patients, both backed by UK NICE recommendations and designed for rapid, on-site use without cold-chain logistics as part of a broader growth strategy in domestic and international healthcare markets. At its latest Annual General Meeting, all resolutions proposed to shareholders were duly passed with strong, though not unanimous, support across the proxy votes, reinforcing the company’s governance agenda and providing a mandate for management to continue executing its commercial and strategic plans in the pharmacogenetic testing space.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Genedrive PLC announced the initiation of a ‘test of change’ pilot program in NHS Grampian and NHS Western Isles to utilize its CYP2C19 ID Kit for stroke patients in remote and rural areas. The pilot is supported by Scotland’s Centre for Sustainable Delivery and aims to evaluate the impact of rapid genetic testing on treatment outcomes, potentially paving the way for widespread adoption across Scotland. The initiative highlights Genedrive’s leadership in pharmacogenetic testing and its commitment to enhancing healthcare accessibility and precision, especially for underserved regions.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Genedrive plc has launched an interactive investor hub aimed at enhancing communication with shareholders and stakeholders. This platform allows users to engage directly with the company, submit questions, and receive updates, thereby fostering transparency and direct dialogue. The initiative is part of Genedrive’s strategy to maintain open communication in a fast-paced environment, ensuring that investors have a reliable source for company updates and insights.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Genedrive plc has secured a shareholder loan agreement with David Nugent, a significant shareholder, to extend its cash runway and support its strategic goals. The loan, valued at up to £1.0 million, will be drawn in two tranches, with the first tranche expected to extend the company’s cash runway into February 2026. This financial support is seen as a positive step for Genedrive, as it continues to execute its commercial and strategic objectives, potentially enhancing its market position and benefiting stakeholders.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Genedrive plc has released its 2025 Annual Report and Accounts, now accessible on their website, with the Annual General Meeting scheduled for 31 December 2025. The company continues to focus on growth through market expansion and strategic acquisitions, leveraging its innovative pharmacogenetic testing products, which are gaining traction in the healthcare industry.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Genedrive plc reported a significant financial turnaround with a 100% increase in revenue to £1 million and a reduced post-tax loss of £5.2 million for the year ending June 2025. The company achieved several operational milestones, including the CE-certification of its Genedrive® CYP2C19 ID Kit, facilitating its commercial progress in the EU. The product has been integrated into various NHS programs and is being used in clinical settings like Salford Royal Hospital. Genedrive also secured a positive value assessment from Scotland’s Health Technology group, leading to government investment in pharmacogenetic testing. Additionally, the Genedrive® MT-RNR1 ID Kit received a conditional recommendation from NICE and is in use across several UK hospitals, with plans for further implementation. The company is expanding its market reach internationally, with strategic partnerships and regulatory engagements in regions like the Middle East and the US.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Genedrive plc announced it will release its preliminary financial results for the year ending June 2025 on December 5, 2025. The company will host a live investor presentation on December 8, 2025, led by CEO Gino Miele and CFO Russ Shaw. This announcement underscores Genedrive’s commitment to transparency and engagement with its investors, as it continues to focus on growth through in-market sales, geographic expansion, and strategic mergers and acquisitions.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Genedrive plc has announced the successful results of a pilot program study on CYP2C19 genotype testing, presented at the UK Stroke Forum. The study supports the NHS’s implementation guide for using this testing to guide Clopidogrel prescriptions after ischemic stroke or TIA. The Genedrive® CYP2C19 ID Kit demonstrated a higher identification rate of patients unlikely to respond to Clopidogrel, impacting prescription practices positively. The test’s rapid results availability aligns with NHS goals, offering significant value by potentially saving bed days and healthcare professional hours, thus enhancing patient care and reducing costs.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Genedrive plc has announced the publication of the NHS implementation guide for CYP2C19 genotype testing, which supports prescribing decisions for stroke patients. The guide highlights the advantages of rapid testing, such as immediate results that facilitate timely treatment decisions, reducing the need for follow-up appointments. The Genedrive® CYP2C19 ID Kit is noted as the preferred rapid testing platform, and the company has been focusing on commercial efforts at the trust and Integrated Care Board level, as rapid testing funding must be sourced locally.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Genedrive plc has announced the national rollout of its Genedrive® MT-RNR1 ID Kit across NHS Scotland, a move that aims to reduce the risk of deafness in newborns requiring antibiotic treatment in neonatal intensive care units. This initiative, supported by NHS Greater Glasgow and Clyde, is expected to significantly enhance patient care by allowing for rapid genetic testing and informed treatment decisions, ultimately improving health outcomes and quality of life for newborns and their families.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Genedrive plc has announced the agreement of terms for a potential £1 million shareholder loan from David Nugent, a significant shareholder. The loan, which will be secured against the company’s assets, is intended to improve Genedrive’s working capital position, allowing it to continue its operations and strategic growth in the pharmacogenetic testing market. The loan will be provided in two tranches, with the first being interest-free and the second incurring a one-off charge, highlighting the financial support and confidence from stakeholders in Genedrive’s future prospects.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Genedrive plc has announced the implementation of its Genedrive® MT-RNR1 ID Kit at Dublin’s Rotunda Hospital Neonatal Intensive Care Unit, marking its first international deployment outside the UK. This implementation, funded by the Rotunda Foundation, is part of the ‘Early Identification of Susceptibility to Gentamicin Induced Hearing Loss’ programme. The kit’s deployment is seen as a validation of its market fit, offering rapid bedside testing to identify babies at risk of significant hearing loss, thereby enhancing patient care and reducing the risk of gentamicin-induced hearing loss. The initiative is supported by the ÉISTIGÍ project and the Charlotte Stoker Fund, highlighting the growing acceptance and potential of pharmacogenetic testing in neonatal care.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Genedrive plc announced that it is in discussions with David Nugent, a significant shareholder, regarding a potential loan of up to £1 million to support the company’s operations. This potential financial backing is seen as a positive development for Genedrive, as it seeks to strengthen its financial position and continue its growth strategy in the pharmacogenetic testing industry.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Genedrive plc has announced a Memorandum of Understanding with the Kingdom of Saudi Arabia’s Ministry of Health to pilot the Genedrive® MT-RNR1 ID Kit under the ‘Generations Hear’ initiative. This collaboration aligns with Saudi Vision 2030, aiming to transform healthcare through precision medicine and preventive care. The initiative is expected to enhance Genedrive’s market presence in Saudi Arabia and contribute to the country’s healthcare transformation goals, potentially impacting future national healthcare strategies.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Genedrive plc has announced the exercise of warrants related to its Equity Prepayment facility, resulting in the issuance of 4,708,584 new ordinary shares. These shares will be admitted to trading on AIM, increasing the company’s total issued share capital to 1,029,603,992 ordinary shares. This move is part of Genedrive’s strategy to enhance its financial flexibility and support its growth initiatives in the pharmacogenetic testing market. The new shares will be available for trading on 30 October 2025, and shareholders can use this updated share capital figure for regulatory compliance purposes.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Genedrive plc announced that none of the resolutions proposed at their General Meeting were passed, impacting their planned Equity Financing. This outcome leaves the company without the authority to issue warrants for the financing announced in September 2025, potentially accelerating the need for alternative funding to maintain operations beyond 2025. The company is engaging with major shareholder David Nugent but has not made significant progress in securing additional capital. Genedrive’s board remains open to alternative financing proposals to support its growth and strategic objectives.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Genedrive plc is addressing concerns raised by a significant shareholder regarding its recent equity financing strategy. The company has explored various financing options and emphasizes that the current equity financing is crucial for extending its cash runway and supporting its operations, including potential market launches. The board highlights the importance of shareholder support for the proposed resolutions at the upcoming general meeting, as failure to secure financing could severely impact the company’s financial stability, operations, and stakeholder relationships.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Genedrive plc addressed speculation regarding its recent equity financing, clarifying that it was the only viable option after exploring various financing alternatives. The company engaged with potential financiers and shareholders but did not receive more favorable offers or acquisition interest. The equity financing has extended Genedrive’s cash runway to the end of 2025, but the company warns of financial uncertainty if additional funding is not secured. The board emphasizes the importance of shareholder support in upcoming resolutions to avoid potential protective measures for creditors.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.